We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Iq-ai Limited | LSE:IQAI | London | Ordinary Share | JE00BD4H0R42 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.55 | 1.50 | 1.60 | 1.55 | 1.55 | 1.55 | 113,265 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Florists | 536k | -512k | -0.0028 | -5.54 | 2.83M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/12/2021 16:17 | Found this on Iqai partner website new research paper from Kathleen Here’s the latest instalment in our news updates from Blackford Platform Partners. Visualization and analytical solutions developer Imaging Biometrics highlighted a new paper in which IB Neuro, the company’s MR dynamic susceptibility contrast (DSC) perfusion platform, demonstrated clinical application throughout all phases of brain tumor management. Neurosurgery Open, Volume 2, Issue 4, December 2021 ABSTRACT BACKGROUND AND IMPORTANCE Distinction of brain tumor progression from treatment effect on postcontrast magnetic resonance imaging (MRI) is an ongoing challenge in the management of brain tumor patients. A newly emerging MRI biomarker called fractional tumor burden (FTB) has demonstrated the ability to spatially distinguish high-grade brain tumor from treatment effect with important implications for surgical management and pathological diagnosis. CLINICAL PRESENTATION A 58-yr-old male with glioblastoma was treated with standard concurrent chemoradiotherapy (CRT) after initial resection. Throughout follow-up imaging, the distinction of tumor progression from treatment effect was of concern. The surgical report from a redo resection indicated recurrent glioblastoma, while the tissue sent for pathological diagnosis revealed no tumor. Presurgical FTB maps confirmed the spatial variation of tumor and treatment effect within the contrast-agent enhancing lesion. Unresected lesion, shown to be an active tumor on FTB, was the site of substantial tumor growth postresection. CONCLUSION This case report introduces the idea that a newly developed MRI biomarker, FTB, can provide information of tremendous benefit for surgical management, pathological diagnosis as well as subsequent treatment management decisions in high-grade glioma. | spurs90 | |
30/12/2021 15:47 | That's because someone was looking for 5.75p to sell a few at that time.Now, I can buy 75k at 5.9p, but that's the limit.I can still sell 350,000 in one hit. | festario | |
30/12/2021 15:35 | You might want to change broker I just managed to get another 64k at 5.9 lol!! | spurs90 | |
30/12/2021 12:25 | Incidentally, try testing the market.I can buy a maximum of 25k shares under 6pBut, for the first time in years, I can sell up to 400,000 shares in one hit, before it goes to indicative only. Price to sell 399,000 shares 5.55p | festario | |
30/12/2021 12:18 | That's not a ramp by the way, it's just saying what small cap stocks tend to do, especially in the pharmaceutical or tech sector, when projects with big potential are announced. | festario | |
30/12/2021 10:23 | I expect this to start building now, in a controlled manner, up to the point where Phase 1 news is issued.A stellar run up, due to the anticipation of Phase 2 and 3 could see this go to levels we haven't seen before. | festario | |
29/12/2021 09:55 | Prof Kathleen Schmainda, PhD, co-founder of Imaging Biometrics (@IQAI_IB subsidiary), shares some of the background and status of IQAI's sponsored Phase I Clinical Trial. [...] Fast Facts: 1 billion MRI scans worldwide. 40% use gadolinium (40 million administrations worldwide). 50 tons of gad administered annually. >$1B worldwide annual market. [...] | howdlep | |
22/12/2021 13:17 | I watched as well Fest. Mighty impressive!!! | joeblogg2 | |
22/12/2021 13:01 | It's on YouTube and via Twitter by the way. | festario | |
22/12/2021 13:01 | I've just watched the Proactive interview with Kathleen Schmainda. It concerns the Phase 1 trials for the brain tumour drug.In February and March, I'll be looking for any institutional investors taking a slice of this. | festario | |
17/12/2021 19:34 | AIM has been dead the last few months. Have to take a long term view here. | rock star | |
17/12/2021 09:18 | On some companies, today's RNS would have brought a flood of buying and a £50m market cap instantly. | festario | |
16/12/2021 08:42 | Stocks across the board being sold down. | rock star | |
15/12/2021 12:23 | At least you cut some our Festario when they were a bit higher. Really going down the tubes now it seems. End of year Blues rather than a Santa Rally. | clocktower | |
15/12/2021 11:19 | Heard it all before | festario | |
14/12/2021 08:37 | Let’s be under no illusion you need to be prepared to hold here for 2/3 years to see the big returns. | rock star | |
13/12/2021 12:22 | Ooh.. RNS! Oh, is that all..? | festario | |
03/12/2021 08:53 | Little chance of the price heading above 7.5p near term. 12.4m warrants @7.5p have one month to run. Would give cash of £930k if taken up. Will need a big one to land to blast through that level. If warrants don’t get converted then another fund raise likely in H1 2022. Pressure on management to deliver deal in next month. | rock star | |
02/12/2021 14:09 | I know Waterloo by the way, and his knowledge on SNG has helped many. But that thread is a guild thread and is seen by a privileged few.Unless the information reaches beyond ADVFN, the impact on trading is negligible.Having said that, IQAI is extremely illiquid.So, if I was to dump a million shares today, the price would be down 10% at least.Similarly if I was to add a million, then we'd be at nearly 7p again.As it is, no one is interested in IQAI, and haven't been for well over a year. It makes me wonder what the nomad are actually doing, and why the house broker haven't issued any guidance at all on this stock. | festario | |
02/12/2021 14:06 | Agreed because nobody I am aware of that posts on this thread has the inside knowledge about the software etc the company is selling and the inside on what clients are paying for the product. The letter set out the potential growth without a question of doubt imo. It's just a matter of time before the roses bloom. | clocktower | |
02/12/2021 13:58 | In reality, if anything groundbreaking is discussed or unearthed here, unless it hits the Twitter crew, nothing would happen.Unfortunately | festario | |
02/12/2021 13:49 | F - well researched postings on ADVFN threads can make an impact on the share price - you just have to go and look at the MIN thread and read over a period of time what waterloo01 posted by way of example - a very knowledgeable poster that obtained information that was freely available if you followed the access to news in those areas it concerned. Many purchased on reading the postings and links that were provided over a long period of time, ahead of the market being aware of the facts. So you are very mistaken if you think that in all cases these threads make no impact. Most I grant you, is just chit chat and must be taken with a big pinch of salt and the facts have a lot more impact than any chit chat, I agree. | clocktower | |
02/12/2021 13:39 | How do you work that out?If you think that anything that I, or anyone else on these boards says affects the share price, then you are out of your mind. | festario | |
02/12/2021 13:11 | Give it a rest Fest. Stick to the other board with your negative, self-loathing, 'I've messed up and Christmas is cancelled' BS. You're only contributing to what you fear the most with this drivel | bdjones1985 | |
02/12/2021 13:00 | There is little to be positive about Sir. | festario |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions